CJC 1295 DAC

CJC‑1295 DAC (100mg)

Description: CJC‑1295 DAC (Drug Affinity Complex) is a long‑acting synthetic analog of growth hormone–releasing hormone (GHRH). Engineered with DAC technology, it binds to albumin, significantly extending its half‑life and allowing sustained stimulation of endogenous growth hormone release. At a 100mg specification, this peptide is ideal for large‑scale or extended research protocols requiring consistent activity and reproducibility.

Key Specifications:

• Form: Lyophilized peptide powder
• Purity: ≥ 98% (HPLC verified)
• Molecular Weight: ~3647 Da
• Sequence: Modified GHRH analog with DAC attachment
• Storage: Stable at −20°C; reconstitute with sterile water before use

Research Benefits:

• Enables studies on long‑term growth hormone secretion and pituitary stimulation.
• Supports investigations into muscle development, tissue repair, and metabolic regulation.
• Provides insight into anti‑aging pathways and regenerative biology.
• Useful in exploring extended peptide activity and pharmacokinetics compared to shorter‑acting analogs.

Why Researchers Choose CJC‑1295 DAC (100mg): The DAC modification ensures prolonged biological activity, reducing the frequency of administration in experimental models. Its stability, purity, and extended half‑life make CJC‑1295 DAC a trusted peptide for advanced research into endocrine modulation, metabolism, and regenerative science.